Ultrasound targeting of Q-starch/miR-197 complexes for topical treatment of psoriasis

J Control Release. 2018 Aug 28:284:103-111. doi: 10.1016/j.jconrel.2018.05.040. Epub 2018 Jun 2.

Abstract

Psoriasis is a common, worldwide autoinflammatory, incurable skin disease. miR-197 has therapeutic potential for psoriasis since it can down-regulate the expression of both IL-22RA1 and IL-17RA, subunits of the receptors of IL-22 and IL-17, respectively, which are key cytokines in the disease. Although miR-197 has the potential to treat the disease, several inherent physical barrier properties of the skin challenge miRNA's delivery to the target skin cells. In the present study, we evaluated a therapeutic approach that combines the use of ultrasound (US) as a means to enhance skin permeability with quaternized starch (Q-starch) as an miRNA delivery carrier. This resulted in decreased expression of the miR-197 target proteins and in a significant reduction in the psoriatic activity markers. Our results demonstrate the potential of combinations of US and Q-starch/miR-197 complexes for the topical skin treatment of psoriasis.

Keywords: Psoriasis; Starch; Topical gene delivery; Transdermal; Ultrasound; miR-197.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Animals
  • Drug Carriers / chemistry*
  • Drug Delivery Systems / methods*
  • Humans
  • Mice
  • Mice, SCID
  • MicroRNAs / administration & dosage*
  • MicroRNAs / pharmacokinetics
  • MicroRNAs / therapeutic use
  • Psoriasis / pathology
  • Psoriasis / therapy*
  • Receptors, Interleukin / analysis
  • Receptors, Interleukin-17 / analysis
  • Skin Absorption
  • Starch / chemistry*
  • Swine
  • Ultrasonic Waves

Substances

  • Drug Carriers
  • MIRN197 microRNA, human
  • MicroRNAs
  • Receptors, Interleukin
  • Receptors, Interleukin-17
  • interleukin-22 receptor
  • Starch